Metabolic syndrome, prediabetes, and brain abnormalities onmri in patients with manifest arterial disease: The smart-mr study

Diabetes Care

Volumn 37, Issue 9, 2014, Pages 2515-2521

  Tiehuis, Audrey M ^a   Van Der Graaf, Yolanda ^a   Mali, Willem P T M ^a   Vincken, Koen ^a   Muller, Majon ^b   Geerlings, Mirjam I ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; ARTERY DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN INFARCTION; BRAIN SIZE; BRAIN TISSUE; BRAIN VENTRICLE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MANIFEST ARTERIAL DISEASE; METABOLIC SYNDROME X; NERVOUS SYSTEM PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBESITY; PROSPECTIVE STUDY; SKULL; WHITE MATTER; WHITE MATTER HYPERINTENSITY; AGING; BRAIN DISEASES; CEREBRAL ARTERY DISEASE; COMPLICATION; CORONARY ARTERY DISEASE; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR;

AGING; BRAIN DISEASES; CEREBRAL ARTERIAL DISEASES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84906701270     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0154     Document Type: Article

References (40)

1. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-2242.
2. Yaffe K, Blackwell T, KanayaAM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63:658-663.
3. Muller M, van Raamt F, Visseren FL, et al.; SMART Study. Metabolic syndrome and cognition in patients with manifest atherosclerotic disease: the SMART study. Neuroepidemiology 2010;34:83-89.
4. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. Diabetes Care 2006;29:2539-2548.
5. Cavalieri M, Ropele S, Petrovic K, et al. Metabolic syndrome, brain magnetic resonance imaging, and cognition. Diabetes Care 2010;33: 2489-2495.
6. Knopman DS, Mosley TH, Catellier DJ, Sharrett AR; Atherosclerosis Risk in Communities (ARIC) Study. Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology 2005;65:876-881.
7. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 2005;64:1704-1711.
8. Bokura H, Yamaguchi S, Iijima K, Nagai A, Oguro H. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke 2008; 39:1607-1609.
9. Chen HJ, Bai CH, Yeh WT, Chiu HC, Pan WH. Influence of metabolic syndrome and general obesity on the risk of ischemic stroke. Stroke 2006;37:1060-1064.
10. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005;36:1366-1371.
11. Kwon HM, Kim BJ, Lee SH, Choi SH, Oh BH, Yoon BW. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 2006;37:466-470.
12. Chen XY, Thomas GN, Chen YK, Chan JC, Wong KS. Atherosclerotic vascular disease rather than metabolic syndrome predicts ischemic stroke in diabetic patients. Cerebrovasc Dis 2010;30:374-379.
13. Park K, Yasuda N, Toyonaga S, et al. Significant association between leukoaraiosis and metabolic syndrome in healthy subjects. Neurology 2007;69:974-978.
14. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006;119:812-819.
15. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006;5:64-74.
16. Wassink AM, van der Graaf Y, Olijhoek JK, Visseren FL; SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2008;29: 213-223.
17. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
18. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999;15: 773-781.
19. Wassink AM, Van Der Graaf Y, Soedamah- Muthu SS, SpieringW, Visseren FLj; Smart Study Group. Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease. Diab Vasc Dis Res 2008;5: 114-122.
20. Anbeek P, Vincken KL, van Bochove GS, van Osch MJ, van der Grond J. Probabilistic segmentation of brain tissue in MR imaging. Neuroimage 2005;27:795-804.
21. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education.
22. Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-3421.
23. Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. J Neurosci 2003;23:3295-3301.
24. Geerlings MI, Appelman APA, Vincken KL, et al.; SMART Study Group. Brain volumes and cerebrovascular lesions on MRI in patients with atherosclerotic disease. The SMART-MR study. Atherosclerosis 2010;210:130-136.
25. Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL. Normative estimates of crosssectional and longitudinal brain volume decline in aging and AD. Neurology 2005;64: 1032-1039.
26. DeCarli C, Massaro J, Harvey D, et al. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging 2005;26: 491-510.
27. Ikram MA, Vrooman HA, Vernooij MW, et al. Brain tissue volumes in the general elderly population. The Rotterdam Scan Study. Neurobiol Aging 2008;29:882-890.
28. Brickman AM, Schupf N, Manly JJ, et al. Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol 2008;65:1053-1061.
29. Mungas D, Jagust WJ, Reed BR, et al. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. Neurology 2001;57:2229-2235.
30. Kramer JH, Mungas D, Reed BR, et al. Longitudinal MRI and cognitive change in healthy elderly. Neuropsychology 2007;21: 412-418.
31. Kalmijn S, Foley D,White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu- Asia aging study. Arterioscler Thromb Vasc Biol 2000;20:2255-2260.
32. Brands AM, Kessels RP, Hoogma RP, et al. Cognitive performance, psychological wellbeing, and brain magnetic resonance imaging in older patients with type 1 diabetes. Diabetes 2006;55:1800-1806.
33. Lunetta M, Damanti AR, Fabbri G, Lombardo M, Di Mauro M, Mughini L. Evidence by magnetic resonance imaging of cerebral alterations of atrophy type in young insulindependent diabetic patients. J Endocrinol Invest 1994;17:241-245.
34. Lobnig BM, Krömeke O, Optenhostert-Porst C, Wolf OT. Hippocampal volume and cognitive performance in long-standing Type 1 diabetic patients without macrovascular complications. Diabet Med 2006;23:32-39.
35. Musen G, Lyoo IK, Sparks CR, et al. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 2006;55:326-333.
36. Tiehuis AM, van der Graaf Y, Visseren FL, et al.; SMART Study Group. Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 2008;39:1600-1603.
37. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol 2008;7:184-190.
38. Wolf H, Hensel A, Arendt T, Kivipelto M, Winblad B, Gertz HJ. Serum lipids and hippocampal volume: the link to Alzheimer's disease? Ann Neurol 2004;56:745-748.
39. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:1987-1994.
40. Olesen OF, Dagø L. High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils. Biochem Biophys Res Commun 2000;270: 62-66.